Deerfield Management Company, L.P. (Series C) Arvinas, Inc. Transaction History

Deerfield Management Company, L.P. (Series C)

$5.38 Billion
Q3 2024

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$14.19 - $42.33 $91,085 - $271,716	6,419 New	6,419 $264,000
Q1 2021 May 17, 2021	SELL	$58.19 - $91.37 $4.36 Million - $6.85 Million	-75,000 Closed	0 $0
Q4 2020 Feb 16, 2021	SELL	$20.19 - $84.93 $10.9 Million - $45.8 Million	-539,156 Reduced 87.79%	75,000 $6.37 Million
Q3 2020 Nov 16, 2020	SELL	$22.99 - $36.34 $9.07 Million - $14.3 Million	-394,500 Reduced 39.11%	614,156 $14.5 Million
Q2 2020 Aug 14, 2020	SELL	$29.88 - $56.74 $6.1 Million - $11.6 Million	-204,266 Reduced 16.84%	1,008,656 $33.8 Million
Q1 2020 May 15, 2020	BUY	$33.0 - $54.5 $4.11 Million - $6.8 Million	124,688 Added 11.46%	1,212,922 $48.9 Million
Q4 2019 Feb 14, 2020	BUY	$15.39 - $44.38 $2.57 Million - $7.41 Million	167,000 Added 18.13%	1,088,234 $44.7 Million
Q4 2018 Feb 14, 2019	SELL	$11.19 - $18.56 $3.5 Million - $5.8 Million	-312,500 Reduced 25.33%	921,234 $11.8 Million
Q3 2018 Nov 14, 2018	BUY	$16.05 - $16.87 $19.8 Million - $20.8 Million	1,233,734 New	1,233,734 $20.8 Million

Others Institutions Holding ARVN

# of Institutions

229

Shares Held

68.4M

Call Options Held

226K

Put Options Held

285K

Vanguard Group Inc Valley Forge, PA

7.01M
Shares

$134 Million
0.0% of portfolio
Eco R1 Capital, LLC San Francisco, CA

6.73M
Shares

$128 Million
7.19% of portfolio
Black Rock Inc. New York, NY

6.26M
Shares

$119 Million
0.0% of portfolio
Price T Rowe Associates Inc Baltimore, MD

3.85M
Shares

$73.5 Million
0.01% of portfolio
Rtw Investments, LP New York, NY

2.78M
Shares

$53.1 Million
1.09% of portfolio

View Full List

About ARVINAS, INC.

Ticker ARVN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 53,205,300
Market Cap $1.02B
Description
Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor ...

More about ARVN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Deerfield Management Company, L.P. (Series C), based on Form 13F filings with the SEC.

News

Stay updated on Deerfield Management Company, L.P. (Series C) with notifications on news.

Account